The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted
20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy …

The traditional platform of using embryonated chicken eggs for the production of influenza
vaccines has several drawbacks including the inability to meet the volume of required doses …

Background We hypothesize that perinatal exposures, in particular the human microbiome
and maternal nutrition during pregnancy, interact with the genetic predisposition to cause an …

Adjuvants may promote immune responses: by recruiting professional antigen‐presenting
cells (APC s) to the vaccination site, increasing the delivery of antigens to APC s, or by …

Influenza virus, a highly mutable respiratory pathogen, causes significant disease nearly
every year. Current vaccines are designed to protect against circulating influenza strains of a …

Background: Influenza is a severe disease burden among all age groups. This study aimed
to review the efficacy of inactivated influenza vaccines with MF59 adjuvant and non …

Background Pregnant women were suspected to be at particular risk when H1N1pnd09
influenza became pandemic in 2009. Our primary objective was to compare the immune …

The influenza virus is a human pathogen that causes epidemics every year, as well as
potential pandemic outbreaks, as occurred in 2009. Vaccination has proven to be sufficient …

While currently used influenza vaccines are designed to induce neutralizing antibodies, little
is known on T cell responses induced by these vaccines. The 2009 pandemic provided us …

Background Although oil-in-water adjuvants improve pandemic influenza vaccine efficacy,
AS03 versus MF59 adjuvant comparisons in A (H1N1) pdm09 pandemic vaccines are …